Woebot

Market position

Press and third-party review coverage describe Woebot as an early and category-defining entrant in AI mental health chatbots and, for much of its life, the most clinically researched consumer AI therapy chatbot, publishing the first randomized controlled trial of an AI therapy chatbot. Following the 2025 consumer shutdown, one independent review identifies Wysa as the most clinically validated consumer AI therapy chatbot available, and cites competition from newer LLM-based chatbots and crowded consumer demand as pressures on Woebot's consumer business.

The company emphasizes clinically authored, scripted conversations grounded in evidence-based therapeutic approaches and a published research base, including evidence that users form a human-level therapeutic bond with the agent — a design that a third-party review characterizes as more consistent and safer than LLM-based alternatives, though sometimes more scripted in feel.

Technology

Woebot is a rule-based relational agent: conversations are scripted by clinical writers and psychologists rather than generated by large language models, using CBT, IPT and DBT techniques. The company describes an AI-powered platform incorporating artificial intelligence and natural language processing that can be configured for different products, intended uses and patient populations. Learning is described as combining aggregate statistical analysis of user responses with direct user feedback used to refine conversation flows and classification.

Go-to-market

Distribution combined a direct-to-consumer app on iOS and Android — including access-code-based unlocking supplied through referral partners — with direct sales to virtual primary care companies, payers and IDNs; the company said 2021 Series B proceeds would expand its team and go-to-market activities.

Individual consumers seeking mental health support, including adults and adolescents, and organizations such as virtual primary care companies, payers and integrated delivery networks. Early Facebook Messenger availability was restricted to users aged 18 and over.

Geography

Headquartered in San Francisco, California, with press releases issued from San Francisco.

History

Woebot was created by Alison Darcy, a clinical research psychologist at Stanford University, who began collaborating with Andrew Ng's lab on applications of AI to mental health before leaving academia to build a direct-to-consumer product. An early version was tested on 70 college students reporting depressive symptoms, with results published in JMIR Mental Health in 2017. Woebot launched first on Facebook Messenger in 2017 and as a standalone iOS app in January 2018. In May 2021 the WB001 postpartum depression solution received FDA Breakthrough Device designation and the company published a large-scale study on therapeutic bond formation; in July 2021 it closed a $90 million Series B. Founder Alison Darcy was named to the 2023 TIME100 AI list, and the company was included in Newsweek's inaugural list of the World's Best Digital Health Companies. The consumer app was shut down in June 2025.

Risks & controversies

Early distribution via Facebook Messenger raised privacy questions, which the company said it addressed through disclosure that users remained subject to Facebook's privacy terms and by building a standalone app. Woebot for Adults and Woebot for Adolescents are not FDA evaluated, cleared or approved, and the ORCHA certification the company cites does not denote FDA clearance or approval. A third-party review attributes the June 2025 consumer app shutdown to market saturation, competition from LLM-based chatbots, the cost and slowness of FDA pathways, and consumer subscription churn and customer acquisition costs, and notes the postpartum depression regulatory pathway never produced a marketed prescription product.